MannKind
Commercializes Afrezza, FUROSCIX and V-Go while manufacturing Tyvaso DPI for United Therapeutics.
$3.95
After-hours close0.00 (0.00%)
At close$3.95(−2.71%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 58.28%186.14M sharesInsiders 2.44%7.78M sharesOther 39.28%125.47M shares
Shares outstanding 319.39M · Float 303.10M · 94.9% free float
Institutions13F, as of Jun 30, 2026
268 holders · 186.14M shares · 52 new positions · 147 increased · 63 reduced · 43 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 32.13M | 10.06% | +3.53M | Aug 7, 2026 |
| Rubric Capital Management LP | 18.00M | 5.64% | +14.38M | Aug 14, 2026 |
| State Street Corp | 16.17M | 5.06% | −2.51M | Aug 7, 2026 |
| Vanguard Capital Management LLC | 13.17M | 4.12% | +278.3K | Aug 13, 2026 |
| Geode Capital Management, LLC | 7.95M | 2.49% | +442.1K | Aug 12, 2026 |
| Wellington Management Group LLP | 7.84M | 2.46% | +4.56M | Aug 14, 2026 |
| Frazier Life Sciences Management, L.P. | 6.60M | 2.07% | +700.0K | Aug 14, 2026 |
| Deep Track Capital, LP | 6.00M | 1.88% | +6.00Mnew | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| State Street Corporation | 6.10% | 18.68M | 13G | May 12, 2026 ↗ |
| Rubric Capital Management LP | 5.83% | 18.00M | 13G | Aug 14, 2026 ↗ |
| Vanguard Capital Management | 5.00% | 15.45M | 13G | Jul 31, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Michael Castagna | director, officer: Chief Executive Officer | 2.43M | 0.76% | Jul 17, 2026 |
| Stuart A. Tross | officer: Chief People & Workpl Officer | 1.06M | 0.33% | Jul 17, 2026 |
| David Thomson | officer: EVP Genl Counsel & Secretary | 797.6K | 0.25% | Jul 17, 2026 |
| Steven B. Binder | director | 785.9K | 0.25% | Aug 10, 2026 |
| Sanjay R. Singh | officer: EVP Technical Operations | 479.0K | 0.15% | Jul 17, 2026 |
| Burkhard Blank | officer: EVP Chief Medical Officer | 460.8K | 0.14% | Jul 17, 2025 |
| Lauren M. Sabella | officer: EVP Operations | 349.8K | 0.11% | Jul 17, 2025 |
| Dominic Marasco | officer: Pres, Endocrine Business Unit | 343.4K | 0.11% | Jul 17, 2026 |
| Christopher B. Prentiss | officer: Chief Financial Officer | 318.7K | 0.10% | Jul 17, 2026 |
| Ajay Ahuja | officer: Chief Medical Officer | 318.2K | 0.10% | Nov 12, 2025 |
1 ten-percent owner holds 8.40M shares by Form 4, outside the officers-and-directors figure above · 28 people have not refiled in the last 18 months (3.51M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 7, 2026 | Steven B. Binderdirector | Sale | 39,051 | $4.06 | 785,867 |
| Jul 17, 2026 | Steven B. Binderdirector | Sale | 52,485 | $4.06 | 824,918 |
| Jul 17, 2026 | David Thomsonofficer: EVP Genl Counsel & Secretary | Sale | 24,109 | $4.05 | 797,554 |
| May 12, 2026 | David Thomsonofficer: EVP Genl Counsel & Secretary | Sale | 3,033 | $3.29 | 826,299 |
| May 12, 2026 | Steven B. Binderdirector | Sale | 16,940 | $3.29 | 808,008 |
| Mar 10, 2026 | Michael Castagnadirector, officer: Chief Executive Officer | Purchase | 100,000 | $2.59 | 2,575,911 |
| Jan 8, 2026 | Stuart A. Trossofficer: Chief People & Workpl Officer | Sale | 47,006 | $6.33 | 985,007 |
| Dec 17, 2025 | Michael Castagnadirector, officer: Chief Executive Officer | Sale | 65,804 | $6.01 | 2,504,792 |
| Dec 16, 2025 | Michael Castagnadirector, officer: Chief Executive Officer | Sale | 21,310 | $6.00 | 2,504,792 |
| Dec 2, 2025 | David Thomsonofficer: EVP Genl Counsel & Secretary | Sale | 147,780 | $5.57 | 841,719 |
CongressHouse and Senate disclosures
Not reported.